Study of Velcade and Thalidomide in Patients With Myelodysplasia

Inclusion Criteria:

• Myelodysplastic syndrome with a IPSS score of 0.5 or greater
• May have had prior chemo/radiotherapy for another malignancy or myelodysplasia
• ECOG performance status of 0-2
• Life expectancy greater than 3 months
• Total bilirubin </+ 2xULN
• ALT and AST </+ 3xULN
• Calculated creatinine clearance > 30 ml/min
• Use of appropriate method of contraception during the study
• ANC > 0.5 x 10(9)
• Platelet count > 30 x 10(9)
• Consideration of treatment with 5 azacytidine is encouraged by not required

Exclusion Criteria:

• Ejection fraction < 40%
• myocardial infarction within 6 months of enrollment of New York Heart Association Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
• Women who are pregnant or breast-feeding
• Major surgery within 4 weeks prior to enrollment
• >/= grade 2 peripheral neuropathy within 14 days prior to enrollment
• Uncontrolled intercurrent illness
• Serious medical or psychiatric illness that could potentially interfere with the completion of treatment
• Hypersensitivity to bortezomib, boron, or mannitol
• Received an investigational drug within 14 days of enrollment